TELA BioTELA
About: TELA Bio Inc is a United States-based medical technology company. The company is involved in developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. Its reinforced tissue matrices called OviTex improve the clinical outcomes and reduce costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. The company's second portfolio of products, the OviTex PRS Reinforced Tissue Matrix, addresses unmet needs in plastic and reconstructive surgery.
Employees: 227
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
620% more call options, than puts
Call options by funds: $36K | Put options by funds: $5K
64% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 14
16% more funds holding
Funds holding: 58 [Q1] → 67 (+9) [Q2]
6.38% more ownership
Funds ownership: 84.13% [Q1] → 90.51% (+6.38%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q1] → 4 (+0) [Q2]
11% less capital invested
Capital invested by funds: $118M [Q1] → $105M (-$12.7M) [Q2]
35% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 23
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
Canaccord Genuity Caitlin Cronin 27% 1-year accuracy 3 / 11 met price target | 382%upside $12 | Buy Maintained | 4 Oct 2024 |
Lake Street Frank Takkinen 54% 1-year accuracy 7 / 13 met price target | 221%upside $8 | Buy Maintained | 13 Aug 2024 |
Canaccord Genuity Caitlin Cronin 27% 1-year accuracy 3 / 11 met price target | 382%upside $12 | Buy Maintained | 13 Aug 2024 |
JMP Securities David Turkaly 33% 1-year accuracy 9 / 27 met price target | 382%upside $12 | Market Outperform Maintained | 13 Aug 2024 |
Piper Sandler Matt O'Brien 43% 1-year accuracy 20 / 47 met price target | 221%upside $8 | Overweight Maintained | 13 Aug 2024 |
